The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
07
05
2020
accepted:
10
11
2020
revised:
02
10
2020
pubmed:
22
12
2020
medline:
24
6
2021
entrez:
21
12
2020
Statut:
ppublish
Résumé
Cholinergic drugs acting at M1/M4 muscarinic receptors hold promise for the treatment of symptoms associated with brain disorders characterized by cognitive impairment, mood disturbances, or psychosis, such as Alzheimer's disease or schizophrenia. However, the brain-wide functional substrates engaged by muscarinic agonists remain poorly understood. Here we used a combination of pharmacological fMRI (phMRI), resting-state fMRI (rsfMRI), and resting-state quantitative EEG (qEEG) to investigate the effects of a behaviorally active dose of the M1/M4-preferring muscarinic agonist xanomeline on brain functional activity in the rodent brain. We investigated both the effects of xanomeline per se and its modulatory effects on signals elicited by the NMDA-receptor antagonists phencyclidine (PCP) and ketamine. We found that xanomeline induces robust and widespread BOLD signal phMRI amplitude increases and decreased high-frequency qEEG spectral activity. rsfMRI mapping in the mouse revealed that xanomeline robustly decreased neocortical and striatal connectivity but induces focal increases in functional connectivity within the nucleus accumbens and basal forebrain. Notably, xanomeline pre-administration robustly attenuated both the cortico-limbic phMRI response and the fronto-hippocampal hyper-connectivity induced by PCP, enhanced PCP-modulated functional connectivity locally within the nucleus accumbens and basal forebrain, and reversed the gamma and high-frequency qEEG power increases induced by ketamine. Collectively, these results show that xanomeline robustly induces both cholinergic-like neocortical activation and desynchronization of functional networks in the mammalian brain. These effects could serve as a translatable biomarker for future clinical investigations of muscarinic agents, and bear mechanistic relevance for the putative therapeutic effect of these class of compounds in brain disorders.
Identifiants
pubmed: 33342996
doi: 10.1038/s41386-020-00916-0
pii: 10.1038/s41386-020-00916-0
pmc: PMC8115158
doi:
Substances chimiques
Muscarinic Agonists
0
Pyridines
0
Receptor, Muscarinic M1
0
Receptor, Muscarinic M4
0
Thiadiazoles
0
xanomeline
9ORI6L73CJ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1194-1206Références
Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MDB, et al. Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res. 2000;42:249–59. https://doi.org/10.1016/S0920-9964(99)00138-3
doi: 10.1016/S0920-9964(99)00138-3
pubmed: 10785583
Andersen MB, Fink-Jensen A, Peacock L, Gerlach J, Bymaster F, Lundbaek JA, et al. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology. 2003;28:1168–75. https://doi.org/10.1038/sj.npp.1300151
doi: 10.1038/sj.npp.1300151
pubmed: 12700711
Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 2003;9:159–86. https://doi.org/10.1111/j.1527-3458.2003.tb00247.x
doi: 10.1111/j.1527-3458.2003.tb00247.x
pubmed: 12847557
pmcid: 6741650
Martino G, Puma C, Yu XH, Gilbert AK, Coupal M, Markoglou N, et al. The M1/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action. Pain. 2011;152:2852–60. https://doi.org/10.1016/j.pain.2011.09.017
doi: 10.1016/j.pain.2011.09.017
pubmed: 22018972
Thorn CA, Moon J, Bourbonais CA, Harms J, Edgerton JR, Stark E, et al. Striatal, HIppocampal, And Cortical Networks Are Differentially Responsive to the M4- and M1-muscarinic acetylcholine receptor mediated effects of xanomeline. ACS Chem Neurosci. 2019;10:1753–64. https://doi.org/10.1021/acschemneuro.8b00625
doi: 10.1021/acschemneuro.8b00625
pubmed: 30480428
Picciotto MR, Higley MJ, Mineur YS. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron. 2012;76:116–29. https://doi.org/10.1016/j.neuron.2012.08.036
doi: 10.1016/j.neuron.2012.08.036
pubmed: 23040810
pmcid: 3466476
Moran SP, Maksymetz J, Conn PJ. Targeting muscarinic acetylcholine receptors for the treatment of psychiatric and neurological disorders. Trends Pharmacol Sci. 2019;40:1006–20. https://doi.org/10.1016/j.tips.2019.10.007
doi: 10.1016/j.tips.2019.10.007
pubmed: 31711626
pmcid: 6941416
Verma S, Kumar A, Tripathi T, Kumar A. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer’s disease therapy. J Pharm Pharmacol. 2018;70:985–93. https://doi.org/10.1111/jphp.12919
doi: 10.1111/jphp.12919
pubmed: 29663387
Felder CC, Goldsmith PJ, Jackson K, Sanger HE, Evans DA, Mogg AJ, et al. Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases. Neuropharmacology. 2018;136:449–58. https://doi.org/10.1016/j.neuropharm.2018.01.028
doi: 10.1016/j.neuropharm.2018.01.028
pubmed: 29374561
Erskine D, Taylor J-P, Bakker G, Brown AJH, Tasker T, Nathan PJ. Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. Drug Discov Today. 2019;24:2307–14. https://doi.org/10.1016/j.drudis.2019.08.009
doi: 10.1016/j.drudis.2019.08.009
pubmed: 31499186
Melancon BJ, Tarr JC, Panarese JD, Wood MR, Lindsley CW. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer’s disease. Drug Discov Today. 2013;18:1185–99. https://doi.org/10.1016/j.drudis.2013.09.005
doi: 10.1016/j.drudis.2013.09.005
pubmed: 24051397
Avery EE, Baker LD, Asthana S. Potential role of muscarinic agonists in Alzheimer’s Disease. Drugs Aging. 1997;11:450–9. https://doi.org/10.2165/00002512-199711060-00004
doi: 10.2165/00002512-199711060-00004
pubmed: 9413702
Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54:465–73. https://doi.org/10.1001/archneur.1997.00550160091022
doi: 10.1001/archneur.1997.00550160091022
pubmed: 9109749
Cui YH, Si W, Yin L, An SM, Jin J, Deng SN, et al. A novel derivative of xanomeline improved memory function in aged mice. Neurosci Bull. 2008;24:251–7. https://doi.org/10.1007/s12264-008-0204-5
doi: 10.1007/s12264-008-0204-5
pubmed: 18668154
pmcid: 5552585
W Si, X Zhang, Y Niu, H Yu, X Lei, H Chen, et al. A novel derivative of xanomeline improves fear cognition in aged mice, 2010. https://doi.org/10.1016/j.neulet.2010.02.031
D Wang, L Yang, J Su, Y Niu, X Lei, J Xiong, et al. Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline, 2011. https://doi.org/10.1016/j.bbrc.2011.05.120
Sullivan RJ, Allen JS, Otto C, Tiobech J, Nero K. Effects of chewing betel nut (Areca catechu) on the symptoms of people with schizophrenia in Palau, Micronesia. Br J Psychiatry. 2000;177:174–8. https://doi.org/10.1192/bjp.177.2.174
doi: 10.1192/bjp.177.2.174
pubmed: 11026959
Scarr E, Dean B. Muscarinic receptors: Do they have a role in the pathology and treatment of schizophrenia? J Neurochem. 2008;107:1188–95. https://doi.org/10.1111/j.1471-4159.2008.05711.x
doi: 10.1111/j.1471-4159.2008.05711.x
pubmed: 18957051
Shannon HE, Hart JC, Bymaster FP, Calligaro DO, Delapp NW, Mitch CH, et al. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J Pharmacol Exp Ther. 1999;290:901–7.
pubmed: 10411607
Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, et al. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther. 2001;299:782–92.
pubmed: 11602695
Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dub S, Mallinckrodt C, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165:1033–9. https://doi.org/10.1176/appi.ajp.2008.06091591
doi: 10.1176/appi.ajp.2008.06091591
pubmed: 18593778
Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry. 2007;12:232–46. https://doi.org/10.1038/sj.mp.4001924
doi: 10.1038/sj.mp.4001924
pubmed: 17146471
Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther. 2008;117:232–43. https://doi.org/10.1016/j.pharmthera.2007.09.009
doi: 10.1016/j.pharmthera.2007.09.009
pubmed: 18082893
Baker S, Chin CL, Basso AM, Fox GB, Marek GJ, Day M. Xanomeline modulation of the blood oxygenation level-dependent signal in awake rats: development of pharmacological magnetic resonance imaging as a translatable pharmacodynamic biomarker for central activity and dose selection. J Pharmacol Exp Ther. 2012;341:263–73. https://doi.org/10.1124/jpet.111.188797
doi: 10.1124/jpet.111.188797
pubmed: 22267203
De Simoni S, Schwarz AJ, O’Daly OG, Marquand AF, Brittain C, Gonzales C, et al. Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. Neuroimage. 2013;64:75–90.
doi: 10.1016/j.neuroimage.2012.09.037
Doyle OM, De Simoni S, Schwarz AJ, Brittain C, O’Daly OG, Williams SCR, et al. Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents. J Pharmacol Exp Ther. 2013;345:151–60.
doi: 10.1124/jpet.112.201665
Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, et al. Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial. JAMA Psychiatry. 2018;75:11–19. https://doi.org/10.1001/jamapsychiatry.2017.3572
doi: 10.1001/jamapsychiatry.2017.3572
pubmed: 29167877
Javitt DC, Lee M, Kantrowitz JT, Martinez A. Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia. Schizophr Res. 2018;191:51–60. https://doi.org/10.1016/j.schres.2017.06.023
doi: 10.1016/j.schres.2017.06.023
pubmed: 28666633
Mehta MA, Schmechtig A, Kotoula V, McColm J, Jackson K, Brittain C, et al. Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects. Psychopharmacology. 2018;235:1875–86. https://doi.org/10.1007/s00213-018-4877-9
doi: 10.1007/s00213-018-4877-9
pubmed: 29564482
Errico F, D’Argenio V, Sforazzini F, Iasevoli F, Squillace M, Guerri G, et al. A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice. Transl Psychiatry. 2015;5:e512 https://doi.org/10.1038/tp.2015.2
doi: 10.1038/tp.2015.2
pubmed: 25689573
pmcid: 4445752
Gozzi A, Schwarz AJ. Large-scale functional connectivity networks in the rodent brain. Neuroimage. 2016;127:496–509. https://doi.org/10.1016/j.neuroimage.2015.12.017
doi: 10.1016/j.neuroimage.2015.12.017
pubmed: 26706448
Lowry JP, Boutelle MG, Fillenz M. Measurement of brain tissue oxygen at a carbon paste electrode can serve as an index of increases in regional cerebral blood flow. J Neurosci Methods. 1997;71:177–82. https://doi.org/10.1016/S0165-0270(96)00140-9
doi: 10.1016/S0165-0270(96)00140-9
pubmed: 9128153
Li J, Schwarz AJ, Gilmour G. Relating translational neuroimaging and amperometric endpoints: utility for neuropsychiatric drug discovery. Curr Top Behav Neurosci. 2016;28:397–421. https://doi.org/10.1007/7854_2016_1
doi: 10.1007/7854_2016_1
pubmed: 27023366
Zacharias N, Musso F, Müller F, Lammers F, Saleh A, London M, et al. Ketamine effects on default mode network activity and vigilance: a randomized, placebo-controlled crossover simultaneous fMRI/EEG study. Hum Brain Mapp. 2020;41:107–19. https://doi.org/10.1002/hbm.24791
doi: 10.1002/hbm.24791
pubmed: 31532029
Ye T, Bartlett MJ, Schmit MB, Sherman SJ, Falk T, Cowen SL. Ten-hour exposure to low-dose ketamine enhances corticostriatal cross-frequency coupling and hippocampal broad-band gamma oscillations. Front Neural Circuits. 2018;12:61 https://doi.org/10.3389/fncir.2018.00061
doi: 10.3389/fncir.2018.00061
pubmed: 30150926
pmcid: 6099120
Greene R. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus. 2001;11:569–77. https://doi.org/10.1002/hipo.1072
doi: 10.1002/hipo.1072
pubmed: 11732709
Farber NB. The NMDA receptor hypofunction model of psychosis. Ann N. Y Acad Sci. 2003;1003:119–30.
doi: 10.1196/annals.1300.008
Gass N, Schwarz AJ, Sartorius E, Schenker E, Risterucci C, Spedding L, et al. Sub-anesthetic ketamine modulates intrinsic BOLD connectivity within the hippocampal-prefrontal circuit in the rat. Neuropsychopharmacology. 2013;39:895–906.
doi: 10.1038/npp.2013.290
Gozzi A, Large C, Schwarz A, Bertani S, Crestan V, Bifone A. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology. 2008;33:1690–703.
doi: 10.1038/sj.npp.1301547
Gozzi A, Schwarz A, Crestan V, Bifone A. Drug-anaesthetic interaction in phMRI: the case of the psychotomimetic agent phencyclidine. Magn Reson Imaging. 2008;26:999–1006. https://doi.org/10.1016/j.mri.2008.01.012
doi: 10.1016/j.mri.2008.01.012
pubmed: 18486387
Gozzi A, Herdon H, Schwarz A, Bertani S, Crestan V, Turrini G, et al. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacology. 2008;201:273–84. https://doi.org/10.1007/s00213-008-1271-z
doi: 10.1007/s00213-008-1271-z
pubmed: 18704372
Li J, Ishiwari K, Conway MW, Francois J, Huxter J, Lowry JP, et al. Dissociable effects of antipsychotics on ketamine-induced changes in regional oxygenation and inter-regional coherence of low frequency oxygen fluctuations in the rat. Neuropsychopharmacology. 2014;39:1635–44. https://doi.org/10.1038/npp.2014.10
doi: 10.1038/npp.2014.10
pubmed: 24442094
pmcid: 4023136
Watt ML, Rorick-Kehn L, Shaw DB, Knitowski KM, Quets AT, Chesterfield AK, et al. The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype. Neuropsychopharmacology. 2013;38:2717–26. https://doi.org/10.1038/npp.2013.186
doi: 10.1038/npp.2013.186
pubmed: 23907402
pmcid: 3828543
Ferrari L, Turrini G, Crestan V, Bertani S, Cristofori P, Bifone A, et al. A robust experimental protocol for pharmacological fMRI in rats and mice. J Neurosci Methods. 2012;204:9–18. https://doi.org/10.1016/j.jneumeth.2011.10.020
doi: 10.1016/j.jneumeth.2011.10.020
pubmed: 22068031
Sforazzini F, Schwarz AJ, Galbusera A, Bifone A, Gozzi A. Distributed BOLD and CBV-weighted resting-state networks in the mouse brain. Neuroimage. 2014;87:403–15. https://doi.org/10.1016/j.neuroimage.2013.09.050
doi: 10.1016/j.neuroimage.2013.09.050
pubmed: 24080504
Zhan Y, Paolicelli RC, Sforazzini F, Weinhard L, Bolasco G, Pagani F, et al. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci. 2014;17:400–6. https://doi.org/10.1038/nn.3641
doi: 10.1038/nn.3641
pubmed: 24487234
Bertani S, Carboni L, Criado A, Michielin F, Mangiarini L, Vicentini E. Circadian profile of peripheral hormone levels in Sprague-Dawley rats and in common marmosets (Callithrix jacchus). Vivo. 2010;24:827–36.
Seidel WF, Maze M, Dement WC, Edgar DM. Alpha-2 adrenergic modulation of sleep: time-of-day-dependent pharmacodynamic profiles of dexmedetomidine and clonidine in the rat. J Pharmacol Exp Ther. 1995;275:263–73.
pubmed: 7562559
Van Gelder RN, Edgar DM, Dement WC. Real-time automated sleep scoring: validation of a microcomputer-based system for mice. Sleep. 1991;14:48–55. https://doi.org/10.1093/sleep/14.1.48
doi: 10.1093/sleep/14.1.48
pubmed: 1811319
Gozzi A, Ceolin L, Schwarz A, Reese T, Bertani S, Crestan V, et al. A multimodality investigation of cerebral hemodynamics and autoregulation in pharmacological MRI. Magn Reson Imaging. 2007;25:826–33. https://doi.org/10.1016/j.mri.2007.03.003
doi: 10.1016/j.mri.2007.03.003
pubmed: 17451905
Liska A, Bertero A, Gomolka R, Sabbioni M, Galbusera A, Barsotti N, et al. Homozygous loss of autism-risk gene CNTNAP2 results in reduced local and long-range prefrontal functional connectivity, Homozygous Loss Autism-Risk Gene Cntnap2 Results Reduc. Local Long-Range Prefrontal Funct. Connect. 2016;060335. https://doi.org/10.1101/060335
Phillips KG, Cotel MC, McCarthy AP, Edgar DM, Tricklebank M, O’Neill MJ, et al. Differential effects of NMDA antagonists on high frequency and gamma EEG oscillations in a neurodevelopmental model of schizophrenia. Neuropharmacology. 2012;62:1359–70. https://doi.org/10.1016/j.neuropharm.2011.04.006
doi: 10.1016/j.neuropharm.2011.04.006
pubmed: 21521646
Muthukumaraswamy SD, Shaw AD, Jackson LE, Hall J, Moran R, Saxena N. Evidence that subanesthetic doses of ketamine cause sustained disruptions of NMDA and AMPA-mediated frontoparietal connectivity in humans. J Neurosci. 2015;35:11694–706. https://doi.org/10.1523/JNEUROSCI.0903-15.2015
doi: 10.1523/JNEUROSCI.0903-15.2015
pubmed: 26290246
pmcid: 4540803
Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the” right stuff”? Schizophr Bull. 2000;26:119.
doi: 10.1093/oxfordjournals.schbul.a033430
Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41–51.
doi: 10.1016/j.schres.2004.09.009
Gozzi A, Apar J, Giovanelli A, Bertollini C, Crestan V, Schwarz AJ, et al. A neural switch for active and passive fear. Neuron. 2010;67:656–66.
doi: 10.1016/j.neuron.2010.07.008
Poorthuis RB, Enke L, Letzkus JJ. Cholinergic circuit modulation through differential recruitment of neocortical interneuron types during behaviour. J Physiol. 2014;592:4155–64. https://doi.org/10.1113/jphysiol.2014.273862
doi: 10.1113/jphysiol.2014.273862
pubmed: 24879871
pmcid: 4215768
Lawrence JJ. Cholinergic control of GABA release: emerging parallels between neocortex and hippocampus. Trends Neurosci. 2008;31:317–27. https://doi.org/10.1016/j.tins.2008.03.008
doi: 10.1016/j.tins.2008.03.008
pubmed: 18556072
Perry KW, Nisenbaum LK, George CA, Shannon HE, Felder CC, Bymaster FP. The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. Biol Psychiatry. 2001;49:716–25. https://doi.org/10.1016/S0006-3223(00)01017-9
doi: 10.1016/S0006-3223(00)01017-9
pubmed: 11313039
Sato A, Sato Y. Cholinergic neural regulation of regional cerebral blood flow. Alzheimer Dis Assoc Disord. 1995;9:28–38. https://doi.org/10.1097/00002093-199505000-00007
Yamada M, Lamping KG, Duttaroy A, Zhang W, Cui Y, Bymaster FP, et al. Cholinergic dilation of cerebral blood vessels is abolished in M5 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci. 2001;98:14096–101.
doi: 10.1073/pnas.251542998
Yamada M, Basile AS, Fedorova I, Zhang W, Duttaroy A, Cui Y, et al. Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology. Life Sci. 2003;74:345–53.
doi: 10.1016/j.lfs.2003.09.022
Grant MKO, El-Fakahany EE. Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor. J Pharmacol Exp Ther. 2005;315:313–9. https://doi.org/10.1124/jpet.105.090134
doi: 10.1124/jpet.105.090134
pubmed: 16002459
Barak S, Weiner I. The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Int J Neuropsychopharmacol. 2011;14:1233–46. https://doi.org/10.1017/S1461145710001549
doi: 10.1017/S1461145710001549
pubmed: 21211109
Gould RW, Nedelcovych MT, Gong X, Tsai E, Bubser M, Bridges TM, et al. State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects. Neuropharmacology. 2016;102:244–53. https://doi.org/10.1016/j.neuropharm.2015.11.016
doi: 10.1016/j.neuropharm.2015.11.016
pubmed: 26617071
Kucewicz MT, Cimbalnik J, Matsumoto JY, Brinkmann BH, Bower MR, Vasoli V, et al. High frequency oscillations are associated with cognitive processing in human recognition memory, A J. Neurol. https://doi.org/10.1093/brain/awu149
Jacob S, Davies G, De Bock M, Hermans B, Wintmolders C, Bottelbergs A, et al. Neural oscillations during cognitive processes in an App knock-in mouse model of Alzheimer’s disease pathology. Sci Rep. 2019;9:16363 https://doi.org/10.1038/s41598-019-51928-w
doi: 10.1038/s41598-019-51928-w
pubmed: 31705038
pmcid: 6841667
Hunt MJ, Olszewski M, Piasecka J, Whittington MA, Kasicki S. Effects of NMDA receptor antagonists and antipsychotics on high frequency oscillations recorded in the nucleus accumbens of freely moving mice. Psychopharmacology. 2015;232:4525–35. https://doi.org/10.1007/s00213-015-4073-0
doi: 10.1007/s00213-015-4073-0
pubmed: 26446869
pmcid: 4646921
Becker R, Braun U, Schwarz AJ, Gass N, Schweiger JI, Weber-Fahr W, et al. Species-conserved reconfigurations of brain network topology induced by ketamine. Transl Psychiatry. 2016;6:e786 https://doi.org/10.1038/tp.2016.53
doi: 10.1038/tp.2016.53
pubmed: 27093068
pmcid: 4872411
Yamada RG, Ueda HR. Molecular mechanisms of REM sleep. Front Neurosci. 2020;13:1402 https://doi.org/10.3389/fnins.2019.01402
doi: 10.3389/fnins.2019.01402
pubmed: 32009883
pmcid: 6972504
Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharm. 1983;79:565–75. https://doi.org/10.1111/j.1476-5381.1983.tb11031.x
doi: 10.1111/j.1476-5381.1983.tb11031.x
Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N. Y Acad Sci. 2003;1003:318–27. https://doi.org/10.1196/annals.1300.020
doi: 10.1196/annals.1300.020
pubmed: 14684455
Moghaddam B, Jackson ME. Glutamatergic animal models of schizophrenia. Ann N. Y Acad Sci. 2003;1003:131–7.
doi: 10.1196/annals.1300.065
Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry. 1999;156:1646–9.
doi: 10.1176/ajp.156.10.1646
Schwarz AJ, Gozzi A, Reese T, Heidbreder CA, Bifone A. Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D3receptor antagonist SB277011A. Magn Reson Imaging. 2007;25:811–20.
doi: 10.1016/j.mri.2007.02.017
De Simoni S, Schwarz AJ, O’Daly OG, Marquand AF, Brittain C, Gonzales C, et al. Test–retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. Neuroimage. 2013;64:75–90. https://doi.org/10.1016/j.neuroimage.2012.09.037
doi: 10.1016/j.neuroimage.2012.09.037
pubmed: 23009959
Deakin JFW, Lees J, McKie S, Hallak JEC, Williams SR, Dursun SM. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry. 2008;65:154–64.
doi: 10.1001/archgenpsychiatry.2007.37
Anticevic A, Corlett PR, Cole MW, Savic A, Gancsos M, Tang Y, et al. N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia. Biol Psychiatry. 2015;77:569–80. https://doi.org/10.1016/j.biopsych.2014.07.022
doi: 10.1016/j.biopsych.2014.07.022
pubmed: 25281999
Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D’Souza DC, et al. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Mol Psychiatry. 2013;8:230–6.
Khalili-Mahani N, Niesters M, van Osch MJ, Oitzl M, Veer I, de Rooij M, et al. Ketamine interactions with biomarkers of stress: A randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men. Neuroimage. 2015;108:396–409. https://doi.org/10.1016/j.neuroimage.2014.12.050
doi: 10.1016/j.neuroimage.2014.12.050
pubmed: 25554429
Joules R, Doyle OM, Schwarz AJ, O’Daly OG, Brammer M, Williams SC, et al. Ketamine induces a robust whole-brain connectivity pattern that can be differentially modulated by drugs of different mechanism and clinical profile. Psychopharmacology. 2015;232:4205–18. https://doi.org/10.1007/s00213-015-3951-9
doi: 10.1007/s00213-015-3951-9
pubmed: 25980482
pmcid: 4600469
Páleníček T, Fujáková M, Brunovský M, Balíková M, Horáček J, Gorman I, et al. Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokinetics. Neuropsychobiology. 2011;63:202–18. https://doi.org/10.1159/000321803
doi: 10.1159/000321803
pubmed: 21422767
Ahnaou A, Huysmans H, Van De Casteele T, Drinkenburg WHIM. Cortical high gamma network oscillations and connectivity: a translational index for antipsychotics to normalize aberrant neurophysiological activity. Transl Psychiatry. 2017;7:1285 https://doi.org/10.1038/s41398-017-0002-9
doi: 10.1038/s41398-017-0002-9
pubmed: 29249806
pmcid: 5802558
Hudson MR, Sokolenko E, O’Brien TJ, Jones NC. NMDA receptors on parvalbumin-positive interneurons and pyramidal neurons both contribute to MK-801 induced gamma oscillatory disturbances: complex relationships with behaviour. Neurobiol Dis. 2020;134:104625 https://doi.org/10.1016/j.nbd.2019.104625
doi: 10.1016/j.nbd.2019.104625
pubmed: 31786371
Moran RJ, Jones MW, Blockeel AJ, Adams RA, Stephan KE, Friston KJ. Losing control under ketamine: suppressed cortico-hippocampal drive following acute ketamine in rats. Neuropsychopharmacology. 2014;40:268–77. https://doi.org/10.1038/npp.2014.184
doi: 10.1038/npp.2014.184
pubmed: 25053181
pmcid: 4443953
Vertes RP, Hoover WB. Projections of the paraventricular and paratenial nuclei of the dorsal midline thalamus in the rat. J Comp Neurol. 2008;508:212–37. https://doi.org/10.1002/cne.21679
doi: 10.1002/cne.21679
pubmed: 18311787
Vertes RP. Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse. 2004;51:32–58. https://doi.org/10.1002/syn.10279
doi: 10.1002/syn.10279
pubmed: 14579424
Thompson KJ, Khajehali E, Bradley SJ, Navarrete JS, Huang XP, Slocum S, et al. DREADD agonist 21 is an effective agonist for muscarinic-based DREADDs in vitro and in vivo. ACS Pharmacol Transl Sci. 2018;1:61–72. https://doi.org/10.1021/acsptsci.8b00012
doi: 10.1021/acsptsci.8b00012
pubmed: 30868140
pmcid: 6407913
Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA. 2008;105:10978–83. https://doi.org/10.1073/pnas.0800567105
doi: 10.1073/pnas.0800567105
pubmed: 18678919
Shah D, Blockx I, Guns P-J, De Deyn PP, Van Dam D, Jonckers E, et al. der Linden, Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI. Neuroimage. 2015;109:151–9. https://doi.org/10.1016/j.neuroimage.2015.01.009
doi: 10.1016/j.neuroimage.2015.01.009
pubmed: 25583611
Byun NE, Grannan M, Bubser M, Barry RL, Thompson A, Rosanelli J, et al. Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100. Neuropsychopharmacology. 2014;39:1578–93. https://doi.org/10.1038/npp.2014.2
doi: 10.1038/npp.2014.2
pubmed: 24442096
pmcid: 4023154
Kurimoto E, Nakashima M, Kimura H, Suzuki M. TAK-071, a muscarinic M1 receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys. PLoS One. 2019;14:e0207969 https://doi.org/10.1371/journal.pone.0207969
doi: 10.1371/journal.pone.0207969
pubmed: 30856192
pmcid: 6411103
Vingerhoets C, Bakker G, Schrantee A, van der Pluijm M, Bloemen OJN, Reneman L, et al. Influence of muscarinic M1 receptor antagonism on brain choline levels and functional connectivity in medication-free subjects with psychosis: a placebo controlled, cross-over study. Psychiatry Res Neuroimaging. 2019;290:5–13. https://doi.org/10.1016/j.pscychresns.2019.06.005
doi: 10.1016/j.pscychresns.2019.06.005
pubmed: 31252222
Power JD, Schlaggar BL, Petersen SE. Studying brain organization via spontaneous fMRI signal. Neuron. 2014;84:681–96. https://doi.org/10.1016/j.neuron.2014.09.007
doi: 10.1016/j.neuron.2014.09.007
pubmed: 25459408
pmcid: 4254503
C Canella, F Rocchi, S Noei, D Gutierrez-Barragan, L Coletta, A Galbusera, et al. Cortical silencing results in paradoxical fMRI overconnectivity, BioRxiv. 2020. https://doi.org/10.1101/2020.08.05.237958